Stablepoint Partners’s AstraZeneca AZN Stock Holding History

Stablepoint Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.09M	Buy	11,000 +258	+2%	+$48.5K	0.29%	101
2026 Q1	$2.12M	Sell	10,742 -653	-6%	-$126K	0.32%	93
2025 Q4	$2.09M	Buy	11,395 +189	+2%	+$33.1K	0.33%	94
2025 Q3	$1.72M	Buy	11,206 +237	+2%	+$35.9K	0.27%	106
2025 Q2	$1.53M	Buy	10,969 +56	+0.5%	+$7.85K	0.26%	112
2025 Q1	$1.6M	Buy	10,913 +416	+4%	+$60.2K	0.29%	102
2024 Q4	$1.38M	Sell	10,497 -469	-4%	-$65.7K	0.25%	119
2024 Q3	$1.71M	Buy	10,966 +87	+0.8%	+$14K	0.31%	93
2024 Q2	$1.7M	Sell	10,879 -623	-5%	-$93.7K	0.33%	91
2024 Q1	$1.56M	Buy	11,502 +2,848	+33%	+$377K	0.32%	99
2023 Q4	$1.17M	Buy	+8,654	New	+$1.13M	0.3%	93

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Stablepoint Partners's AZN Position: Q2 2026 in Review

Stablepoint Partners increased its AstraZeneca (AZN) stake by 2.4% in Q2 2026, buying an estimated $48.5K and bringing the position to 11,000 shares worth $2.09M. The position accounts for 0.29% of the portfolio, ranked #101.

Stablepoint Partners first reported a position in AZN in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.12M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Stablepoint Partners held 11,000 shares of AstraZeneca worth $2.09M as of Q2 2026.
Stablepoint Partners bought 258 AstraZeneca shares in Q2 2026, an estimated $48.5K.
AstraZeneca made up 0.29% of Stablepoint Partners's portfolio in Q2 2026, its #101 holding.
Stablepoint Partners first reported a position in AstraZeneca in Q4 2023 and has held it in 11 quarters since.
Stablepoint Partners's AstraZeneca position peaked at $2.12M in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Stablepoint Partners's 13F filing for Q2 2026, filed 9 Jul 2026.